A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER) Interim analysis

Authors:

Daniel M. Geynisman, Philip Abbosh, Eric A. Ross, Matthew R. Zibelman, Pooja Ghatalia, Fern Anari, Katherine Ansel, James Ryan Mark, Lambros Stamatakis, Jean H. Hoffman-Censits, Rosalia Viterbo, Eric M. Horwitz, Mark A Hallman, R. Katherine Alpaugh, Richard E. Greenberg, Marc C. Smaldone, Robert Guy Uzzo, David Chen, Alexander Kutikov, Elizabeth R. Plimack

  • Follow up continues for the primary endpoint of 2 year MFS in ITT: 81.7% are so far w/o M1 dz
  • 77% of patients on active surveillance are alive, without M1 dz and with their bladder intact
  • 65% of patients on active surveillance have had some form of recurrence: 9/17 being NMIBC with bladder still intact
  • 11.5% of patients on active surveillance have had M1 dz vs. 23.6% in those w/o mut
  • HCRN GU16 257 and A031701 are ongoing
  • Risk adapted bladder preservation is NOT a standard of care

Download Publication